View
comments
A third dose of the Pfizer-BioNTech COVID-19 vaccine could offer strong protection against the Indian 'Delta' variant, data reveals, as a separate study finds protection provided by the vaccine could wane after six months.
New data released by the company on Wednesday showed antibody levels increased five-fold among people ages 18 to 55 who were given the booster shot.
The third dose was especially effecting for the elderly, with antibody levels spiking 11-fold among people aged 65 to 85 who had already received the standard two doses.
In the slides published online, the researchers wrote there there is 'estimated potential for up to 100-fold increase in Delta neutralization post-dose three compared to pre-dose three.'
The new data comes at a welcome time, as separate pre-print research finds that the efficacy of the Pfizer vaccine falls from 96 percent to only 84 percent after six months.
Data from Pfizer shows that the third dose of the company's COVID vaccine can increase antibodies to fight the Delta variant 11-fold in people 65 to 85
The Delta variant continues to spread across the country, making up at least 83 percent of all new infections.
Pfizer
